Search Results - "Wu, Tianshuang"

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Authors: Magnolo, Nina Soung, Jennifer Frew, John et al.

Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3415-3429. 15p.

Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.

Authors: Simpson, Eric L. Silverberg, Jonathan I. Prajapati, Vimal H. et al.

Source: Dermatology & Therapy. Aug2025, Vol. 15 Issue 8, p2061-2076. 16p.

Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial.

Authors: Tyring, Stephen Moore, Angela Morita, Akimchi et al.

Source: Clinical & Experimental Dermatology. Nov2024, Vol. 49 Issue 11, p1347-1355. 9p.

A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.

Authors: Alexis, Andrew F. Gooderham, Melinda Kwatra, Shawn G. et al.

Source: Dermatology & Therapy. Oct2024, Vol. 14 Issue 10, p2877-2887. 11p.

Power analysis in a SMART design: sample size estimation for determining the best embedded dynamic treatment regime.

Authors: Artman, William J Nahum-Shani, Inbal Wu, Tianshuang et al.

Source: Biostatistics; Jul2020, Vol. 21 Issue 3, p432-448, 17p

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.

Authors: Strober, Bruce Armstrong, April Rubant, Simone et al.

Source: Journal of Dermatological Treatment. Nov2022, Vol. 33 Issue 7, p2991-2996. 6p.

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation.

Authors: Odnopozova, Liudmila Edin, Anton Sukharev, Alexey et al.

Source: Dermatology & Therapy. Sep2022, Vol. 12 Issue 9, p2063-2075. 13p.

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.

Authors: Crowley, Jeffrey J. Langley, Richard G. Gordon, Kenneth B. et al.

Source: Dermatology & Therapy. Feb2022, Vol. 12 Issue 2, p561-575. 15p.

Identifying a set that contains the best dynamic treatment regimes.

Authors: ERTEFAIE, ASHKAN TIANSHUANG WU LYNCH, KEVIN G. et al.

Source: Biostatistics; Jan2016, Vol. 17 Issue 1, p135-148, 14p

Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome.

Authors: Seewald, Nicholas J Kidwell, Kelley M Nahum-Shani, Inbal et al.

Source: Statistical Methods in Medical Research. Jul2020, Vol. 29 Issue 7, p1891-1912. 22p.

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.

Authors: Blauvelt, Andrew Leonardi, Craig L. Gooderham, Melinda et al.

Source: JAMA dermatology Jun2020; Vol. 156 (6).

Journal Info: Publisher: American Medical Association ISSN: 2168-6068